Incyte And Mirati Therapeutics Enter To Evaluate INCB99280 And Adagrasib In Patients With KRASG12C-Mutated Solid Tumors November 16, 2022
Promising SRF388 Monotherapy Data in NSCLC announced, Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort November 16, 2022
Imfinzi and Imjudo with chemotherapy approved in the US for patients with mNSCLC based on POSEIDON Phase III trial results November 16, 2022
FDA approves cemiplimab (Libtayo) with platinum-based chemotherapy for the treatment of advanced NSCLC patients with WT EGFR, ALK, or ROS1 November 16, 2022
Updated Findings from the Ph 2 SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC Presented November 4, 2022
Preliminary Ph 1 Clinical Data from ARROS-1 Trial of NVL-520 for Patients with ROS1-Positive NSCLC reported November 4, 2022
Mirati Therapeutics & Aadi Bioscience Partner to Evaluate Adagrasib + Nab-sirolimus in Advanced NSCLC and Other Solid Tumors patients with a KRAS[G12C] Mutation October 19, 2022
US FDA grants Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with LUMAKRAS® (sotorasib) October 19, 2022
PERLA Ph 2 trial Of Jemperli (Dostarlimab) + Chemotherapy In Patients With mNSCLC met the primary endpoint of ORR October 12, 2022
FDA grants Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for 1L NSCLC October 12, 2022
FDA grants Fast Track Designation for Sapanisertib in NRF2-mutated Squamous Lung Cancer October 12, 2022
TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory NSCLC October 5, 2022
Gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Responses in Ovarian Cancer and Mesothelioma October 5, 2022
KEYTRUDA + Chemo Showed Sustained OS Benefit vs Chemo Alone in in KEYNOTE-189 and KEYNOTE-407 trials for mNSCLC September 13, 2022
Tagrisso demonstrated 5.5-year mDFS in the adjuvant treatment of patients with EGFR-mutated lung cancer September 13, 2022
Imfinzi and tremelimumab with chemotherapy demonstrated sustained OS benefit in mNSCLC September 13, 2022
Positive early data announced for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced NSCLC September 13, 2022
FAILED TRIAL: Ph 2 SELECT trial of vopratelimab + pimivalimab combination vs pimivalimab alone did not meet its primary endpoint of mean tumor change in in TISvopra Biomarker-Selected 2L NSCLC Patients September 7, 2022
Ph 3 CodeBreaK 200 trial of LUMAKRAS® (sotorasib) met its primary endpoint of PFS improvement over SoC chemotherapy in KRAS G12C-Mutated NSCLC September 7, 2022
Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways June 13, 2022
